All peptides
Retatrutide
Also known as: LY3437943
Research / Investigational
Retatrutide is a novel triagonist under Phase III development targeting GIP, GLP-1, and glucagon receptors for obesity and type 2 diabetes.
Buy Retatrutide on American Peptides
Affiliate link — we may earn a commission at no extra cost to you.
Overview
Retatrutide is a novel triagonist under Phase III development targeting GIP, GLP-1, and glucagon receptors for obesity and type 2 diabetes.
FDA Approval Status
Not approved by the FDA. Investigational or intended for research purposes only.
Mechanism of Action
Simultaneous agonism of GIP, GLP-1, and glucagon receptors enhances insulin sensitivity, appetite suppression, and energy expenditure.
Current Research
Phase II trials reported ~24% mean weight loss at 48 weeks; Phase III ongoing.
Research strength: Moderate
Potential Medical Uses
- Investigational only
Potential Benefits
- Substantial weight reduction in trials
- Improved glycemic control
Known Side Effects
- Nausea
- Vomiting
- Diarrhea
- Elevated heart rate
Contraindications
- MTC/MEN 2 history
- Pregnancy
Drug Interactions
- Insulin/sulfonylureas
Administration Methods
- Subcutaneous injection weekly
Half-life
~6 days
Reconstitution
Investigational; supplied per trial protocol.
Storage & Handling
Refrigerated per protocol.
References & Sources
Frequently Asked Questions
Information on this page is educational and general in nature. It is not medical advice. Consult a qualified healthcare professional before making any medical decisions.